A. D. Beadell Investment Counsel Lowers stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : A. D. Beadell Investment Counsel reduced its stake in Johnson & Johnson by 2.41% during the most recent quarter end. The investment management company now holds a total of 40,524 shares of Johnson & Johnson which is valued at $5,066,716 after selling 999 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Jul 22, 2016.Johnson & Johnson makes up approximately 4.06% of A. D. Beadell Investment Counsel’s portfolio.

Other Hedge Funds, Including , Conestoga Capital Advisors reduced its stake in JNJ by selling 128 shares or 2.86% in the most recent quarter. The Hedge Fund company now holds 4,351 shares of JNJ which is valued at $544,006. Johnson & Johnson makes up approx 0.04% of Conestoga Capital Advisors’s portfolio.Lathrop Investment Management Corp boosted its stake in JNJ in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 2,849 shares of Johnson & Johnson which is valued at $350,826. Johnson & Johnson makes up approx 0.10% of Lathrop Investment Management Corp’s portfolio.Gierl Augustine Investment Management Inc reduced its stake in JNJ by selling 3,419 shares or 11.55% in the most recent quarter. The Hedge Fund company now holds 26,184 shares of JNJ which is valued at $3,220,632. Johnson & Johnson makes up approx 3.39% of Gierl Augustine Investment Management Inc’s portfolio.Campbell Newman Asset Management Inc boosted its stake in JNJ in the latest quarter, The investment management firm added 28,965 additional shares and now holds a total of 42,323 shares of Johnson & Johnson which is valued at $5,205,729. Johnson & Johnson makes up approx 0.92% of Campbell Newman Asset Management Inc’s portfolio.Mitchell Sinkler Starrpa reduced its stake in JNJ by selling 555 shares or 1.92% in the most recent quarter. The Hedge Fund company now holds 28,392 shares of JNJ which is valued at $3,492,216. Johnson & Johnson makes up approx 4.67% of Mitchell Sinkler Starrpa’s portfolio.

Johnson & Johnson opened for trading at $124.34 and hit $125.32 on the upside on Friday, eventually ending the session at $125.23, with a gain of 0.62% or 0.77 points. The heightened volatility saw the trading volume jump to 70,20,910 shares. Company has a market cap of $344,463 M.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Investors should note that on Jul 20, 2016, Johnson & Johnson announced a cash dividend of $0.2900. The company’s management has announced Aug 3, 2016 as the ex-dividend date and fixed the record date on Aug 5, 2016. The payable date has been fixed on Aug 19, 2016.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.